16 September 2026 editorial review · Item
Rituximab (anti-CD20): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: reviewed; no confirmed content change. Current item
lastReviewed: 2026-08-27. - Claim check: Rituximab initial C-peptide effect and 8.2-month lag checked; RELAY combination remains active follow-up with no posted outcomes. No prevention approval.
- Registry NCT00279305: COMPLETED; updated 2020-05-06; enrollment 87 (ACTUAL); primary completion 2009-04 (ACTUAL); results posted.
- Registry NCT03929601: ACTIVE_NOT_RECRUITING; updated 2026-09-01; enrollment 74 (ACTUAL); primary completion 2027-03-31 (ESTIMATED); results not posted in retrieved record.
- Primary publication/regulatory sources checked or consulted: PMID 19940299; PMID 24026563; PMID 26404926.